The 'Restriction Order' is upgraded, and the antibiotic market faces a major crisis

Recently, the National Health Commission issued the "Notice on Further Strengthening the Management of Antimicrobial Drugs to Contain Drug Resistance", requiring the standardization of drug treatment for infectious diseases caused by pathogenic microorganisms such as bacteria, mycoplasma, chlamydia, rickettsiae, spirochetes, fungi .

Specifically, the "Notice" proposed that the rational use of antimicrobial drugs should be included in the hospital review, public hospital performance assessment, and rational drug use assessment, and the weight of the assessment should be appropriately increased.

In addition, the notice also proposes that medical institutions should scientifically adjust and optimize their antimicrobial drug supply catalogue in accordance with regulations, and manage the rational use of antimicrobial drugs from the source of procurement. Before the end of September 2021, general hospitals above the second level should all join the national antimicrobial clinical application monitoring network and bacterial resistance monitoring network.

It is worth noting that antibiotics are a very important class of antimicrobial drugs, including penicillins, cephalosporins, aminoglycosides, macrolides, tetracyclines, peptides, lincomycins, etc. . For this reason, the industry believes that as the country further strengthens antimicrobial drug management, antibiotic drugs will also be further strictly controlled, and the market will face major challenges.

It is understood that antibiotics are mainly used to treat or prevent certain types of bacterial infections. They can kill bacteria or prevent their spread. Because it has created many medical miracles, many people regard antibiotics as "magic medicine" or equivalent to "anti-inflammatory drugs", mistakenly thinking that antibiotics can treat all inflammations. It is precisely because of this concept that there has been a long-term abuse of antibiotics in China, which has brought adverse reactions to the human body.

In order to solve the harm caused by the abuse of antibiotics to the human body in my country, in recent years, relevant departments in my country have begun to continuously strengthen the management of this drug, and the country and even local governments have issued documents to cancel or restrict the use of antibiotics. For example, in 2004, the "Guiding Principles for the Clinical Application of Antimicrobial Drugs" was promulgated to implement hierarchical management of antimicrobial drugs; in 2005, the "National Bacterial Resistance Monitoring Network" and "Antimicrobial Drug Application Monitoring Network" were established; Application and Bacterial Resistance Monitoring Work" notice; in 2011, relevant national departments began to carry out a three-year special rectification activity; in 2012, the head antibacterial drug management regulations "Administrative Measures for the Clinical Application of Antimicrobial Drugs" were formally implemented; in 2015, "About "Notice on Further Strengthening the Management of Clinical Application of Antibacterial Drugs" was released.

At present, under the continuous influence of the "national anti-resistance policy", the growth rate of antibiotic hospital market sales is gradually slowing down. In addition, it is worth mentioning that in this context, some antibiotic manufacturers have also begun to sell the business or accelerate their transformation. It is reported that on April 23, 2019, Eli Lilly Pharmaceuticals announced the signing of an agreement with the Chinese pharmaceutical company Yiteng Pharmaceutical to sell its antibiotic products. In addition, Kelun Pharmaceutical started its transformation in 2012, and the proportion of its non-infusion products is currently increasing.

Industry insiders believe that in the context of the country's increasing attention to drug safety issues, continuous strengthening of antimicrobial drug management, and continuous increase in the evaluation weight of its use in hospitals, in the future, although the antibiotic market will continue to expand, it will also continue to expand. Subject to more strict control.